Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States Article Swipe
Girishanthy Krishnarajah
,
Victoria Divino
,
Maarten J. Postma
,
Stephen I. Pelton
,
Vamshi Ruthwik Anupindi
,
Mitch DeKoven
,
J Mould-Quevedo
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.3390/vaccines9020080
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.3390/vaccines9020080
Non-egg-based influenza vaccines eliminate the potential for egg-adapted mutations and potentially increase vaccine effectiveness. This retrospective study compared hospitalizations/emergency room (ER) visits and all-cause annualized healthcare costs among subjects aged 4–64 years who received cell-based quadrivalent (QIVc) or standard-dose egg-based quadrivalent (QIVe-SD) influenza vaccine during the 2018–19 influenza season. Administrative claims data (IQVIA PharMetrics® Plus, IQVIA, USA) were utilized to evaluate clinical and economic outcomes. Adjusted relative vaccine effectiveness (rVE) of QIVc vs. QIVe-SD among overall cohort, as well as for three subgroups (age 4–17 years, age 18–64 years, and high-risk) was evaluated using inverse probability of treatment weighting (IPTW) and Poisson regression models. Generalized estimating equation models among the propensity score matched sample were used to estimate annualized all-cause costs. A total of 669,030 recipients of QIVc and 3,062,797 of QIVe-SD were identified after IPTW adjustments. Among the overall cohort, QIVc had higher adjusted rVEs against hospitalizations/ER visits related to influenza, all-cause hospitalizations, and hospitalizations/ER visits associated with any respiratory event compared to QIVe-SD. The adjusted annualized all-cause total costs were higher for QIVe-SD compared to QIVc ((+$461); p < 0.05).
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/vaccines9020080
- https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017
- OA Status
- gold
- Cited By
- 25
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3125941622
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3125941622Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/vaccines9020080Digital Object Identifier
- Title
-
Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United StatesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-01-23Full publication date if available
- Authors
-
Girishanthy Krishnarajah, Victoria Divino, Maarten J. Postma, Stephen I. Pelton, Vamshi Ruthwik Anupindi, Mitch DeKoven, J Mould-QuevedoList of authors in order
- Landing page
-
https://doi.org/10.3390/vaccines9020080Publisher landing page
- PDF URL
-
https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017Direct OA link when available
- Concepts
-
Medicine, Poisson regression, Propensity score matching, Influenza vaccine, Retrospective cohort study, Cohort, Demography, Internal medicine, Environmental health, Vaccination, Immunology, Population, SociologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
25Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 5, 2024: 5, 2023: 5, 2022: 6, 2021: 4Per-year citation counts (last 5 years)
- References (count)
-
25Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3125941622 |
|---|---|
| doi | https://doi.org/10.3390/vaccines9020080 |
| ids.doi | https://doi.org/10.3390/vaccines9020080 |
| ids.mag | 3125941622 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33498724 |
| ids.openalex | https://openalex.org/W3125941622 |
| fwci | 3.73357541 |
| type | article |
| title | Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States |
| biblio.issue | 2 |
| biblio.volume | 9 |
| biblio.last_page | 80 |
| biblio.first_page | 80 |
| topics[0].id | https://openalex.org/T10167 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Influenza Virus Research Studies |
| topics[1].id | https://openalex.org/T10833 |
| topics[1].field.id | https://openalex.org/fields/33 |
| topics[1].field.display_name | Social Sciences |
| topics[1].score | 0.9970999956130981 |
| topics[1].domain.id | https://openalex.org/domains/2 |
| topics[1].domain.display_name | Social Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/3306 |
| topics[1].subfield.display_name | Health |
| topics[1].display_name | Vaccine Coverage and Hesitancy |
| topics[2].id | https://openalex.org/T10118 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9864000082015991 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | SARS-CoV-2 and COVID-19 Research |
| is_xpac | False |
| apc_list.value | 2200 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2382 |
| apc_paid.value | 2200 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2382 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.6664420366287231 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C73269764 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6456983089447021 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q954529 |
| concepts[1].display_name | Poisson regression |
| concepts[2].id | https://openalex.org/C17923572 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5495350956916809 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q7250160 |
| concepts[2].display_name | Propensity score matching |
| concepts[3].id | https://openalex.org/C2780689484 |
| concepts[3].level | 3 |
| concepts[3].score | 0.491792231798172 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q383260 |
| concepts[3].display_name | Influenza vaccine |
| concepts[4].id | https://openalex.org/C167135981 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4589179456233978 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[4].display_name | Retrospective cohort study |
| concepts[5].id | https://openalex.org/C72563966 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4521009922027588 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[5].display_name | Cohort |
| concepts[6].id | https://openalex.org/C149923435 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3747589588165283 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q37732 |
| concepts[6].display_name | Demography |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3220391869544983 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C99454951 |
| concepts[8].level | 1 |
| concepts[8].score | 0.2715253233909607 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[8].display_name | Environmental health |
| concepts[9].id | https://openalex.org/C22070199 |
| concepts[9].level | 2 |
| concepts[9].score | 0.26151102781295776 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q192995 |
| concepts[9].display_name | Vaccination |
| concepts[10].id | https://openalex.org/C203014093 |
| concepts[10].level | 1 |
| concepts[10].score | 0.2527778148651123 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[10].display_name | Immunology |
| concepts[11].id | https://openalex.org/C2908647359 |
| concepts[11].level | 2 |
| concepts[11].score | 0.11139515042304993 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[11].display_name | Population |
| concepts[12].id | https://openalex.org/C144024400 |
| concepts[12].level | 0 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q21201 |
| concepts[12].display_name | Sociology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.6664420366287231 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/poisson-regression |
| keywords[1].score | 0.6456983089447021 |
| keywords[1].display_name | Poisson regression |
| keywords[2].id | https://openalex.org/keywords/propensity-score-matching |
| keywords[2].score | 0.5495350956916809 |
| keywords[2].display_name | Propensity score matching |
| keywords[3].id | https://openalex.org/keywords/influenza-vaccine |
| keywords[3].score | 0.491792231798172 |
| keywords[3].display_name | Influenza vaccine |
| keywords[4].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[4].score | 0.4589179456233978 |
| keywords[4].display_name | Retrospective cohort study |
| keywords[5].id | https://openalex.org/keywords/cohort |
| keywords[5].score | 0.4521009922027588 |
| keywords[5].display_name | Cohort |
| keywords[6].id | https://openalex.org/keywords/demography |
| keywords[6].score | 0.3747589588165283 |
| keywords[6].display_name | Demography |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.3220391869544983 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/environmental-health |
| keywords[8].score | 0.2715253233909607 |
| keywords[8].display_name | Environmental health |
| keywords[9].id | https://openalex.org/keywords/vaccination |
| keywords[9].score | 0.26151102781295776 |
| keywords[9].display_name | Vaccination |
| keywords[10].id | https://openalex.org/keywords/immunology |
| keywords[10].score | 0.2527778148651123 |
| keywords[10].display_name | Immunology |
| keywords[11].id | https://openalex.org/keywords/population |
| keywords[11].score | 0.11139515042304993 |
| keywords[11].display_name | Population |
| language | en |
| locations[0].id | doi:10.3390/vaccines9020080 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210226234 |
| locations[0].source.issn | 2076-393X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2076-393X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Vaccines |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Vaccines |
| locations[0].landing_page_url | https://doi.org/10.3390/vaccines9020080 |
| locations[1].id | pmid:33498724 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Vaccines |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33498724 |
| locations[2].id | pmh:oai:pure.rug.nl:publications/71016920-8f83-448c-a19b-163c3f502ab1 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400420 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | University of Groningen research database (University of Groningen / Centre for Information Technology) |
| locations[2].source.host_organization | https://openalex.org/I169381384 |
| locations[2].source.host_organization_name | University of Groningen |
| locations[2].source.host_organization_lineage | https://openalex.org/I169381384 |
| locations[2].license | cc-by |
| locations[2].pdf_url | https://pure.rug.nl/ws/files/176984083/vaccines_09_00080_v2.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Krishnarajah, G, Divino, V, Postma, M J, Pelton, S, Anupindi, V R, DeKoven, M & Mould-Quevedo, J 2021, 'Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States', Vaccines, vol. 9, no. 2, 80. https://doi.org/10.3390/vaccines9020080 |
| locations[2].landing_page_url | https://research.rug.nl/en/publications/71016920-8f83-448c-a19b-163c3f502ab1 |
| locations[3].id | pmh:oai:doaj.org/article:8aa1d81615a6443f89e4842da17154e8 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | cc-by-sa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Vaccines, Vol 9, Iss 2, p 80 (2021) |
| locations[3].landing_page_url | https://doaj.org/article/8aa1d81615a6443f89e4842da17154e8 |
| locations[4].id | pmh:oai:pubmedcentral.nih.gov:7911861 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S2764455111 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | PubMed Central |
| locations[4].source.host_organization | https://openalex.org/I1299303238 |
| locations[4].source.host_organization_name | National Institutes of Health |
| locations[4].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[4].license | other-oa |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | https://openalex.org/licenses/other-oa |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | Vaccines (Basel) |
| locations[4].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7911861 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5034135253 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Girishanthy Krishnarajah |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210129217 |
| authorships[0].affiliations[0].raw_affiliation_string | Seqirus USA Inc., Summit, NJ 07901, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210129217 |
| authorships[0].institutions[0].ror | https://ror.org/03k879d12 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210129217 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Seqirus (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Girishanthy Krishnarajah |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Seqirus USA Inc., Summit, NJ 07901, USA |
| authorships[1].author.id | https://openalex.org/A5065999728 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-5555-7912 |
| authorships[1].author.display_name | Victoria Divino |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210108991 |
| authorships[1].affiliations[0].raw_affiliation_string | IQVIA, Falls Church, VA 22042, USA |
| authorships[1].institutions[0].id | https://openalex.org/I4210108991 |
| authorships[1].institutions[0].ror | https://ror.org/01mk44223 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210108991 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | IQVIA (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Victoria Divino |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | IQVIA, Falls Church, VA 22042, USA |
| authorships[2].author.id | https://openalex.org/A5016565734 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6306-3653 |
| authorships[2].author.display_name | Maarten J. Postma |
| authorships[2].countries | NL |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I169381384 |
| authorships[2].affiliations[0].raw_affiliation_string | Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, 9700 Groningen, The Netherlands |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I1334415907, https://openalex.org/I169381384 |
| authorships[2].affiliations[1].raw_affiliation_string | Department of Health Sciences, University Medical Centre Groningen (UMCG), University of Groningen, 9700 Groningen, The Netherlands |
| authorships[2].affiliations[2].institution_ids | https://openalex.org/I169381384 |
| authorships[2].affiliations[2].raw_affiliation_string | Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, 9700 Groningen, The Netherlands |
| authorships[2].institutions[0].id | https://openalex.org/I1334415907 |
| authorships[2].institutions[0].ror | https://ror.org/03cv38k47 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1334415907 |
| authorships[2].institutions[0].country_code | NL |
| authorships[2].institutions[0].display_name | University Medical Center Groningen |
| authorships[2].institutions[1].id | https://openalex.org/I169381384 |
| authorships[2].institutions[1].ror | https://ror.org/012p63287 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I169381384 |
| authorships[2].institutions[1].country_code | NL |
| authorships[2].institutions[1].display_name | University of Groningen |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Maarten J. Postma |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, 9700 Groningen, The Netherlands, Department of Health Sciences, University Medical Centre Groningen (UMCG), University of Groningen, 9700 Groningen, The Netherlands, Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, 9700 Groningen, The Netherlands |
| authorships[3].author.id | https://openalex.org/A5030519106 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-4862-5344 |
| authorships[3].author.display_name | Stephen I. Pelton |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1286490081 |
| authorships[3].affiliations[0].raw_affiliation_string | Maxwell Finland Laboratories, Boston Medical Center, Boston, MA 02118, USA |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I111088046, https://openalex.org/I4210136996 |
| authorships[3].affiliations[1].raw_affiliation_string | Department of Epidemiology, Boston University Schools of Medicine and Public Health, Boston, MA 02118, USA |
| authorships[3].institutions[0].id | https://openalex.org/I1286490081 |
| authorships[3].institutions[0].ror | https://ror.org/010b9wj87 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1286490081 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Boston Medical Center |
| authorships[3].institutions[1].id | https://openalex.org/I4210136996 |
| authorships[3].institutions[1].ror | https://ror.org/03bj7kr91 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210136996 |
| authorships[3].institutions[1].country_code | US |
| authorships[3].institutions[1].display_name | Boston Public Schools |
| authorships[3].institutions[2].id | https://openalex.org/I111088046 |
| authorships[3].institutions[2].ror | https://ror.org/05qwgg493 |
| authorships[3].institutions[2].type | education |
| authorships[3].institutions[2].lineage | https://openalex.org/I111088046 |
| authorships[3].institutions[2].country_code | US |
| authorships[3].institutions[2].display_name | Boston University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Stephen I. Pelton |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Epidemiology, Boston University Schools of Medicine and Public Health, Boston, MA 02118, USA, Maxwell Finland Laboratories, Boston Medical Center, Boston, MA 02118, USA |
| authorships[4].author.id | https://openalex.org/A5029255725 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-0385-8657 |
| authorships[4].author.display_name | Vamshi Ruthwik Anupindi |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210108991 |
| authorships[4].affiliations[0].raw_affiliation_string | IQVIA, Falls Church, VA 22042, USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210108991 |
| authorships[4].institutions[0].ror | https://ror.org/01mk44223 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210108991 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | IQVIA (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Vamshi Ruthwik Anupindi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | IQVIA, Falls Church, VA 22042, USA |
| authorships[5].author.id | https://openalex.org/A5011077808 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9346-6202 |
| authorships[5].author.display_name | Mitch DeKoven |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210108991 |
| authorships[5].affiliations[0].raw_affiliation_string | IQVIA, Falls Church, VA 22042, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210108991 |
| authorships[5].institutions[0].ror | https://ror.org/01mk44223 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210108991 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | IQVIA (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Mitch DeKoven |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | IQVIA, Falls Church, VA 22042, USA |
| authorships[6].author.id | https://openalex.org/A5110736746 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | J Mould-Quevedo |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210129217 |
| authorships[6].affiliations[0].raw_affiliation_string | Seqirus USA Inc., Summit, NJ 07901, USA |
| authorships[6].institutions[0].id | https://openalex.org/I4210129217 |
| authorships[6].institutions[0].ror | https://ror.org/03k879d12 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210129217 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Seqirus (United States) |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Joaquin Mould-Quevedo |
| authorships[6].is_corresponding | True |
| authorships[6].raw_affiliation_strings | Seqirus USA Inc., Summit, NJ 07901, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10167 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Influenza Virus Research Studies |
| related_works | https://openalex.org/W2026576563, https://openalex.org/W3196761963, https://openalex.org/W2036193982, https://openalex.org/W213628847, https://openalex.org/W4232168831, https://openalex.org/W4253956144, https://openalex.org/W3023923059, https://openalex.org/W2065417422, https://openalex.org/W2275925001, https://openalex.org/W4214949305 |
| cited_by_count | 25 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 5 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 5 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 5 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 6 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 4 |
| locations_count | 5 |
| best_oa_location.id | doi:10.3390/vaccines9020080 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210226234 |
| best_oa_location.source.issn | 2076-393X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2076-393X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Vaccines |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Vaccines |
| best_oa_location.landing_page_url | https://doi.org/10.3390/vaccines9020080 |
| primary_location.id | doi:10.3390/vaccines9020080 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210226234 |
| primary_location.source.issn | 2076-393X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2076-393X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Vaccines |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/2076-393X/9/2/80/pdf?version=1611630017 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Vaccines |
| primary_location.landing_page_url | https://doi.org/10.3390/vaccines9020080 |
| publication_date | 2021-01-23 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2912473805, https://openalex.org/W2998914842, https://openalex.org/W2889891640, https://openalex.org/W2794531861, https://openalex.org/W2904715936, https://openalex.org/W3046094430, https://openalex.org/W2969322952, https://openalex.org/W2952048915, https://openalex.org/W2979405251, https://openalex.org/W4211222382, https://openalex.org/W4211031111, https://openalex.org/W3007037952, https://openalex.org/W4229810677, https://openalex.org/W2791290311, https://openalex.org/W2979887792, https://openalex.org/W2126049444, https://openalex.org/W2206238447, https://openalex.org/W2110818436, https://openalex.org/W6802582575, https://openalex.org/W2765297310, https://openalex.org/W1966200581, https://openalex.org/W2102976886, https://openalex.org/W2944057814, https://openalex.org/W2904354111, https://openalex.org/W3209818041 |
| referenced_works_count | 25 |
| abstract_inverted_index.A | 121 |
| abstract_inverted_index.p | 179 |
| abstract_inverted_index.as | 77, 79 |
| abstract_inverted_index.of | 70, 96, 123, 126, 130 |
| abstract_inverted_index.or | 37 |
| abstract_inverted_index.to | 59, 116, 150, 163, 176 |
| abstract_inverted_index.The | 165 |
| abstract_inverted_index.age | 86 |
| abstract_inverted_index.and | 9, 22, 62, 89, 100, 128, 154 |
| abstract_inverted_index.any | 159 |
| abstract_inverted_index.for | 6, 80, 173 |
| abstract_inverted_index.had | 142 |
| abstract_inverted_index.the | 4, 45, 109, 138 |
| abstract_inverted_index.vs. | 72 |
| abstract_inverted_index.was | 91 |
| abstract_inverted_index.who | 32 |
| abstract_inverted_index.< | 180 |
| abstract_inverted_index.(ER) | 20 |
| abstract_inverted_index.(age | 83 |
| abstract_inverted_index.IPTW | 135 |
| abstract_inverted_index.QIVc | 71, 127, 141, 177 |
| abstract_inverted_index.This | 14 |
| abstract_inverted_index.USA) | 56 |
| abstract_inverted_index.aged | 29 |
| abstract_inverted_index.data | 51 |
| abstract_inverted_index.rVEs | 145 |
| abstract_inverted_index.room | 19 |
| abstract_inverted_index.used | 115 |
| abstract_inverted_index.well | 78 |
| abstract_inverted_index.were | 57, 114, 132, 171 |
| abstract_inverted_index.with | 158 |
| abstract_inverted_index.(rVE) | 69 |
| abstract_inverted_index.Among | 137 |
| abstract_inverted_index.Plus, | 54 |
| abstract_inverted_index.after | 134 |
| abstract_inverted_index.among | 27, 74, 108 |
| abstract_inverted_index.costs | 26, 170 |
| abstract_inverted_index.event | 161 |
| abstract_inverted_index.score | 111 |
| abstract_inverted_index.study | 16 |
| abstract_inverted_index.three | 81 |
| abstract_inverted_index.total | 122, 169 |
| abstract_inverted_index.using | 93 |
| abstract_inverted_index.years | 31 |
| abstract_inverted_index.(IPTW) | 99 |
| abstract_inverted_index.(IQVIA | 52 |
| abstract_inverted_index.(QIVc) | 36 |
| abstract_inverted_index.0.05). | 181 |
| abstract_inverted_index.4–17 | 84 |
| abstract_inverted_index.4–64 | 30 |
| abstract_inverted_index.IQVIA, | 55 |
| abstract_inverted_index.claims | 50 |
| abstract_inverted_index.costs. | 120 |
| abstract_inverted_index.during | 44 |
| abstract_inverted_index.higher | 143, 172 |
| abstract_inverted_index.models | 107 |
| abstract_inverted_index.sample | 113 |
| abstract_inverted_index.visits | 21, 148, 156 |
| abstract_inverted_index.years, | 85, 88 |
| abstract_inverted_index.18–64 | 87 |
| abstract_inverted_index.669,030 | 124 |
| abstract_inverted_index.Poisson | 101 |
| abstract_inverted_index.QIVe-SD | 73, 131, 174 |
| abstract_inverted_index.against | 146 |
| abstract_inverted_index.cohort, | 76, 140 |
| abstract_inverted_index.inverse | 94 |
| abstract_inverted_index.matched | 112 |
| abstract_inverted_index.models. | 103 |
| abstract_inverted_index.overall | 75, 139 |
| abstract_inverted_index.related | 149 |
| abstract_inverted_index.season. | 48 |
| abstract_inverted_index.vaccine | 12, 43, 67 |
| abstract_inverted_index.Adjusted | 65 |
| abstract_inverted_index.QIVe-SD. | 164 |
| abstract_inverted_index.adjusted | 144, 166 |
| abstract_inverted_index.clinical | 61 |
| abstract_inverted_index.compared | 17, 162, 175 |
| abstract_inverted_index.economic | 63 |
| abstract_inverted_index.equation | 106 |
| abstract_inverted_index.estimate | 117 |
| abstract_inverted_index.evaluate | 60 |
| abstract_inverted_index.increase | 11 |
| abstract_inverted_index.received | 33 |
| abstract_inverted_index.relative | 66 |
| abstract_inverted_index.subjects | 28 |
| abstract_inverted_index.utilized | 58 |
| abstract_inverted_index.vaccines | 2 |
| abstract_inverted_index.((+$461); | 178 |
| abstract_inverted_index.(QIVe-SD) | 41 |
| abstract_inverted_index.2018–19 | 46 |
| abstract_inverted_index.3,062,797 | 129 |
| abstract_inverted_index.all-cause | 23, 119, 152, 168 |
| abstract_inverted_index.egg-based | 39 |
| abstract_inverted_index.eliminate | 3 |
| abstract_inverted_index.evaluated | 92 |
| abstract_inverted_index.influenza | 1, 42, 47 |
| abstract_inverted_index.mutations | 8 |
| abstract_inverted_index.outcomes. | 64 |
| abstract_inverted_index.potential | 5 |
| abstract_inverted_index.subgroups | 82 |
| abstract_inverted_index.treatment | 97 |
| abstract_inverted_index.weighting | 98 |
| abstract_inverted_index.annualized | 24, 118, 167 |
| abstract_inverted_index.associated | 157 |
| abstract_inverted_index.cell-based | 34 |
| abstract_inverted_index.estimating | 105 |
| abstract_inverted_index.healthcare | 25 |
| abstract_inverted_index.high-risk) | 90 |
| abstract_inverted_index.identified | 133 |
| abstract_inverted_index.influenza, | 151 |
| abstract_inverted_index.propensity | 110 |
| abstract_inverted_index.recipients | 125 |
| abstract_inverted_index.regression | 102 |
| abstract_inverted_index.Generalized | 104 |
| abstract_inverted_index.egg-adapted | 7 |
| abstract_inverted_index.potentially | 10 |
| abstract_inverted_index.probability | 95 |
| abstract_inverted_index.respiratory | 160 |
| abstract_inverted_index.adjustments. | 136 |
| abstract_inverted_index.quadrivalent | 35, 40 |
| abstract_inverted_index.Non-egg-based | 0 |
| abstract_inverted_index.PharMetrics® | 53 |
| abstract_inverted_index.effectiveness | 68 |
| abstract_inverted_index.retrospective | 15 |
| abstract_inverted_index.standard-dose | 38 |
| abstract_inverted_index.Administrative | 49 |
| abstract_inverted_index.effectiveness. | 13 |
| abstract_inverted_index.hospitalizations, | 153 |
| abstract_inverted_index.hospitalizations/ER | 147, 155 |
| abstract_inverted_index.hospitalizations/emergency | 18 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5110736746 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 7 |
| corresponding_institution_ids | https://openalex.org/I4210129217 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7099999785423279 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.91918397 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |